RxDoctor Payments Data

David Nava, MD

Internal Medicine · San Antonio, TXNPI 1083234371

Payments from drug & device makers

$2,085in general payments, 2019–2025

Across 76 payments — averaging $27.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$652
  • Dexcom, Inc.$245
  • Bayer$194
  • Boehringer Ingelheim$168
  • Amgen$136
  • TG Therapeutics, Inc.$125
  • plus $566 from 14 others

What the payments were for

  • Food & beverage$2,085100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,085 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$30,011
Medicare patients
80
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide200$231,021
JardianceEmpagliflozin44$67,246
TrulicityDulaglutide37$53,606
EliquisApixaban41$46,604
TradjentaLinagliptin34$32,247
JanuviaSitagliptin Phosphate19$31,469
FarxigaDapagliflozin Propanediol27$25,589
JanumetSitagliptin Phos/Metformin Hcl18$24,123
Janumet XrSitagliptin Phos/Metformin Hcl19$21,707
MounjaroTirzepatide14$21,001
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,587
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$9,439
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$9,398
Tresiba Flextouch U-100Insulin Degludec15$9,037
SymbicortBudesonide/Formoterol Fumarate33$8,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$652$231,021200 claims
Boehringer IngelheimJardiance, Tradjenta$168$99,49278 claims
MerckJanuvia, Janumet, Janumet Xr$34$77,29956 claims
Lilly USA, LLCTrulicity, Mounjaro$48$74,60751 claims
PfizerEliquis$41$46,60441 claims
AstraZenecaFarxiga, Symbicort$35$34,53060 claims
GSKTrelegy Ellipta$21$18,58719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →